Targeting glutamate to treat schizophrenia: lessons from recent clinical studies

Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers

(2016) Carsten Hofmann et al.   PSYCHOPHARMACOLOGY

Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?

(2015) Philipp Singer et al.   CURRENT PHARMACEUTICAL DESIGN

Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic

(2015) T Lencz et al.   MOLECULAR PSYCHIATRY

Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

(2015) Meng-Lin Li et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

The practical management of refractory schizophrenia - the Maudsley Treatment REview and Assessment Team service approach

(2014) K. Beck et al.   ACTA PSYCHIATRICA SCANDINAVICA

A neurobiological hypothesis for the classification of schizophrenia: type a (hyperdopaminergic) and type B (normodopaminergic)

(2014) Oliver D. Howes et al.   BRITISH JOURNAL OF PSYCHIATRY

A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia – Results from the CandleLyte study

(2014) D. Bugarski-Kirola et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia

(2014) Daniel Umbricht et al.   JAMA Psychiatry

Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function

(2013) Arsime Demjaha et al.   BIOLOGICAL PSYCHIATRY

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

(2013) E M P Poels et al.   MOLECULAR PSYCHIATRY

Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia

(2012) Alice Egerton et al.   NEUROPSYCHOPHARMACOLOGY

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

(2011) Bruce J. Kinon et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

(2009) O. D. Howes et al.   SCHIZOPHRENIA BULLETIN